Regulatory Approval, New Appointments, Stock Price Movements, and Other Announcements - Research Report on Pfizer, Warner Chilcott, Rockwell Medical, InterMune, and Ligand

NEW YORK, October 2, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Warner Chilcott plc (NASDAQ: WCRX), Rockwell Medical Inc. (NASDAQ: RMTI), InterMune Inc. (NASDAQ: ITMN), and Ligand Pharmaceuticals Inc. (NASDAQ: LGND). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On September 27, 2013, Reuters reported that Pfizer Inc.'s (Pfizer) antibacterial drug Tygacil increases the risk of death whether used as authorized by the US Food and Drug Administration (FDA) or for unapproved conditions. As reported in the release, the Company must include a warning inside a black box on the drug's label, indicating the risk is of the most serious nature. Kimberly Bencker, a spokeswoman for Pfizer, said that "due to the increase in antibiotic resistance worldwide, Tygacil continues to be an appropriate treatment option for its approved indications." Reuters further added that according to FDA, patients who took Tygacil for authorized uses had a 2.5 % risk of death, compared with a 1.8 % risk of death for those who took other antibacterial drugs. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-29/PFE]

--

Warner Chilcott plc Research Report

On September 27, 2013, Warner Chilcott plc (Warner Chilcott) announced that the US Federal Trade Commission (FTC) has voted to approve Actavis' proposed acquisition of Warner Chilcott. Warner Chilcott stated that the approval has come after Actavis' agreement to a proposed consent order with the FTC, and under the terms of this consent order, and subject to the consummation of the transaction, Actavis will divest four products to Amneal Pharmaceuticals which includes:  Zenchent Fe; its pending application for norethindrone acetate/ethinyl estradiol; its pending application for risedronate sodium; and its approved application for norethindrone acetate/ethinyl estradiol. The Company informed that the closing of the transaction is subject to approval by the Irish High Court and other customary closing conditions. The Full Research Report on Warner Chilcott plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-29/WCRX]

--

Rockwell Medical Inc. Research Report

On September 27, 2013, Rockwell Medical Inc.'s (Rockwell Medical) stock jumped by 16.94% as compared to its previous day's closing price, ending the day at $10.77 on Nasdaq. Rockwell Medical shares have gained 17.07% over the previous three trading sessions, outperforming, the Nasdaq Composite, which gained 0.35% during the same period. The Full Research Report on Rockwell Medical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-29/RMTI]

--

InterMune Inc. Research Report

On September 24, 2013, InterMune Inc. (InterMune) welcomed Andrew Powell as Executive Vice President, General Counsel, and Corporate Secretary for the Company. According to InterMune, in this new role, Mr. Powell will be responsible for managing the Company's legal affairs and will report to Dan Welch, Chairman, CEO and President of InterMune. Commenting on the appointment, Mr. Welch said, "Andrew brings experience in many areas that are key to InterMune's future as our Esbriet sales continue to grow globally, and we plan for anticipated approval and launch of Esbriet in the United States." InterMune informed that prior to this new role Mr. Powell served as Executive Vice President, General Counsel and Secretary at Cornerstone Therapeutics and for more than 25 years. InterMune reported that Powell has practiced law principally in healthcare and biotechnology. The Full Research Report on InterMune Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-29/ITMN]

--

Ligand Pharmaceuticals Inc. Research Report

On September 24, 2013, Ligand Pharmaceuticals Inc. (Ligand) reported that its partner, GlaxoSmithKline plc (GSK), announced that the European Commission has granted an additional indication for Revolade (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adults with chronic hepatitis C infection, where the degree of thrombocytenia is the main factor that prevents the initiation or limiting the ability to maintain optimal interferon (IFN)-based therapy. Ligand stated that thrombocytopenia may prevent initiation and maintenance of peginterferon (pIFN)-based treatment, and consequently reduces a patient's chances of reaching a sustained virologic response (SVR), which is the goal of hepatitis C treatment. John Higgins, President and CEO of Ligand, said, "We are extremely pleased with the decision of the European Commission, and eagerly await the launch of Revolade in the European Union for this indication. This is an important achievement, as otherwise very sick patients suffering with chronic hepatitis C infection with few therapeutic options will now have the opportunity to potentially receive needed treatment." The Full Research Report on Ligand Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-29/LGND]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investors' Reports